• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

作者信息

Shimada Y, Rothenberg M, Hilsenbeck S G, Burris H A, Degen D, Von Hoff D D

机构信息

Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

出版信息

Anticancer Drugs. 1994 Apr;5(2):202-6. doi: 10.1097/00001813-199404000-00011.

DOI:10.1097/00001813-199404000-00011
PMID:8049503
Abstract

CPT-11 (irinotecan hydrochloride, 7-ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxy-camptothecin) is a semisynthetic camptothecin derivative developed in Japan. The inhibitory activity of CPT-11 against human tumor colony-forming units from freshly explanted human tumors was explored using a soft agar cloning system. Final CPT-11 concentrations of 0.3-3.0 micrograms/ml were used for a 1 h exposure. At a concentration of 3.0 micrograms/ml antitumor activity was seen against colorectal, ovarian, nonsmall-cell lung, breast cancer and mesothelioma colony-forming units. CPT-11 should have activity against a broad spectrum of tumors in patients.

摘要

相似文献

1
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Anticancer Drugs. 1994 Apr;5(2):202-6. doi: 10.1097/00001813-199404000-00011.
2
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.7-乙基-10-[4-(1-哌啶基)-1-哌啶基]羰基氧基喜树碱：耐药机制与临床试验
Cancer Chemother Pharmacol. 1994;34 Suppl:S112-7. doi: 10.1007/BF00684874.
3
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20. doi: 10.1093/jnci/84.23.1816.
4
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.非喜树碱和喜树碱拓扑异构酶I抑制剂对骨髓和肿瘤细胞集落形成单位及人肿瘤异种移植的疗效
Mol Cancer Ther. 2008 Oct;7(10):3212-22. doi: 10.1158/1535-7163.MCT-08-0568.
5
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.拓扑异构酶I抑制剂7-乙基-10-(4-[1-哌啶基]-1-哌啶基)-羰氧基喜树碱对儿童和成人中枢神经系统肿瘤异种移植瘤的治疗效果。
Cancer Chemother Pharmacol. 1997;39(3):187-91. doi: 10.1007/s002800050558.
6
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.拓扑异构酶I抑制剂RFS-2000或CPT-11与拓扑异构酶II抑制剂依托泊苷联合使用对人肺癌细胞的辐射增强作用。
Radiother Oncol. 2002 Jan;62(1):61-7. doi: 10.1016/s0167-8140(01)00465-0.
7
In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer.拓扑异构酶-I抑制剂CPT-11对新鲜分离的人胃癌和结直肠癌的体外抗肿瘤作用。
Anticancer Res. 1999 Nov-Dec;19(6B):5451-5.
8
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.拓扑异构酶I抑制剂7-乙基-10-(4-[1-哌啶基]-1-哌啶基)-羰氧基喜树碱对人肿瘤异种移植瘤的治疗效果：在对拓扑异构酶I抑制剂9-二甲基氨基甲基-10-羟基喜树碱产生获得性耐药的肿瘤中体内无交叉耐药性。
Cancer Res. 1993 Jun 15;53(12):2823-9.
9
Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.CPT-11（伊立替康）一种新代谢产物的鉴定：药理学特性及向SN-38的转化
J Pharmacol Exp Ther. 1998 Jul;286(1):578-83.
10
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.人肺癌细胞中CPT-11和SN-38活性的决定因素。
Br J Cancer. 1998 Jun;77(12):2171-6. doi: 10.1038/bjc.1998.362.

引用本文的文献

1
Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.用于癌症治疗的甲氧基聚乙二醇-喜树碱（mPEG-SN38）和甲氧基聚乙二醇-聚乳酸-喜树碱（mPEG-PLA-SN38）胶束的合成、表征及评价
Int J Nanomedicine. 2016 Apr 26;11:1677-86. doi: 10.2147/IJN.S103110. eCollection 2016.
2
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.S-1 联合伊立替康和贝伐珠单抗（SIRB）作为转移性结直肠癌一线治疗的 II 期研究。
Invest New Drugs. 2012 Aug;30(4):1690-6. doi: 10.1007/s10637-011-9743-0. Epub 2011 Sep 6.
3
Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.
羧基封端的 PAMAM-SN38 缀合物：合成、表征和体外评价。
Bioconjug Chem. 2010 Oct 20;21(10):1804-10. doi: 10.1021/bc100094z.
4
Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.使用聚（酰胺 - 胺）树枝状大分子实现7 - 乙基 - 10 - 羟基喜树碱（SN - 38）的潜在口服给药。
Pharm Res. 2008 Jul;25(7):1723-9. doi: 10.1007/s11095-008-9572-9. Epub 2008 Apr 26.
5
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.伊立替康联合5-氟尿嘧啶和亚叶酸作为转移性结直肠癌一线治疗的临床及经济效益。
Br J Cancer. 2002 Jun 5;86(11):1677-83. doi: 10.1038/sj.bjc.6600204.
6
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.伊立替康与雷替曲塞用于晚期胃肠道腺癌患者的I期研究。
Br J Cancer. 2000 Jul;83(2):146-52. doi: 10.1054/bjoc.2000.1192.
7
A risk-benefit assessment of irinotecan in solid tumours.伊立替康用于实体瘤的风险效益评估。
Drug Saf. 1998 Jun;18(6):395-417. doi: 10.2165/00002018-199818060-00002.
8
Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.伊立替康。其药理学特性及在晚期结直肠癌治疗中的临床疗效综述。
Drugs. 1996 Oct;52(4):606-23. doi: 10.2165/00003495-199652040-00013.
9
Preclinical and phase I trials of topoisomerase I inhibitors.
Cancer Chemother Pharmacol. 1994;34 Suppl:S41-5. doi: 10.1007/BF00684862.